Half-Life and Dosing Frequency (concept)

Why dosing frequency differs so much between molecules

About 80% of dosing errors in clinical practice come down to a misunderstanding of one concept: half-life. Not the wrong molecule, not the wrong route, just a shaky mental model of how quickly a body clears a substance. The same molecule can need dosing once a week or four times a day depending on how that clearance behaves, and that is why dosing frequency is such a useful lens on pharmacology. Half-life really is the skeleton key to understanding why drugs are dosed the way they are.

This article won't tell you how to dose anything. What it will do is explain the concept clearly enough that the rest of pharmacokinetics starts to make sense. If you want the formal definition on its own, the glossary entry for half-life is a good companion to this piece.

The definition, stripped back

Half-life (written t½) is the time it takes for the concentration of a substance in the body, usually measured in plasma, to fall to half its current value. That's it. One clean, recursive number.

If a molecule has a half-life of four hours, and you start at a plasma concentration of 100 units, you'll have roughly 50 units at hour four, 25 at hour eight, 12.5 at hour twelve, and so on. The decline follows first-order kinetics for most drugs: a constant fraction eliminated per unit time, not a constant amount. That distinction matters. A drug at 100 units loses 50 in one half-life; a drug at 10 units loses only 5 in the same span of time. The rate is proportional to what's left.

A common mistake is to read half-life as "the time until the drug is gone". It isn't. After one half-life half remains, and after two a quarter remains. The curve flattens as it falls, so the tail can linger far longer than people expect. The general concept is the same one used to describe radioactive decay, which is why the Wikipedia article on half-life is a handy general reference.

The formula that pharmacologists actually use is:

t½ = (0.693 × Vd) ÷ CL

Where Vd is the volume of distribution (how widely the drug spreads through body tissues) and CL is clearance (how efficiently the body removes it, primarily via the liver and kidneys). A drug that buries itself deep in fat tissue will have a high Vd and a long half-life even if the liver would otherwise clear it quickly. This is directly relevant to highly lipophilic cannabinoids; more on that in a moment.

The formula is worth sitting with, because it shows that half-life is not a fixed property of a molecule in the way molecular weight is. It is a derived value. Change the distribution or the clearance and the half-life moves, even though the molecule is identical. That is the root of most of the individual variation discussed later.

Steady state: the goal of repeated dosing

A single dose tells you a lot. Repeated dosing tells you the story that actually matters clinically.

When you dose a substance repeatedly before the previous dose is fully cleared, plasma concentrations accumulate until input equals output. That plateau is called steady state. The rule of thumb: steady state is reached after approximately five half-lives. A molecule with a two-hour half-life reaches steady state in about ten hours. One with a 72-hour half-life takes fifteen days.

Notice what that rule implies. The time to reach the plateau depends only on half-life, not on how large each dose is. A bigger dose raises the plateau; it does not get you there sooner. People often assume otherwise, and the confusion explains a good deal of misplaced impatience with slow-accumulating substances.

This is why loading doses exist. If you need a therapeutic concentration quickly but the drug has a long half-life, waiting five half-lives for natural accumulation is impractical. A higher initial dose front-loads the system; subsequent maintenance doses then keep concentrations within the target range. You'll see this logic applied across prescription schedules, it is not specific to any one drug class. The companion piece on loading dose versus maintenance goes through the idea in more detail.

Setting the interval: peaks, troughs and the therapeutic window

Dosing interval, almost universally, is set at around one half-life. That keeps trough concentrations from dropping too low and peak concentrations from climbing too high. The narrower the therapeutic window (the gap between the effective concentration and the toxic concentration), the more precisely interval matters.

Think of the plasma curve at steady state as a gentle sawtooth. Each dose pushes the concentration up to a peak, then elimination pulls it down towards a trough before the next dose arrives. Shorten the interval and the sawtooth flattens, with smaller swings around a similar average. Lengthen it and the swings widen. For a drug with a wide window, a wobbly curve is tolerable. For one with a narrow window, the same wobble could carry the concentration out of the useful range at either end.

This is also where the practical logic of formulation comes in. Extended-release designs, long-acting analogues and similar approaches are, at heart, attempts to flatten that sawtooth without demanding more frequent administration. They don't change the underlying biology of clearance so much as work around it.

How cannabinoids complicate the picture

Cannabinoids are genuinely interesting from a PK standpoint because they break several of the clean rules above.

Tetrahydrocannabinol (THC) and cannabidiol (CBD) are highly lipophilic, they dissolve readily in fat and distribute widely into adipose tissue and the brain. That gives them large volumes of distribution and, consequently, long terminal half-lives. Published estimates for THC's terminal half-life in frequent users run from 3 to 13 days, because the molecule slowly leaches back out of fat stores long after the acute pharmacological effect has passed. For a casual or occasional user the effective half-life of the active compound is much shorter; hours rather than days, because there's less tissue accumulation.

Route of administration adds another layer. Inhaled THC bypasses the first pass entirely and reaches peak plasma concentration in minutes. Orally ingested THC passes through the gut and liver before entering circulation, a process called first-pass metabolism; which converts a significant proportion to 11-hydroxy-THC, a more potent metabolite with its own distinct half-life. The same nominal dose via two different routes produces completely different concentration-time curves. Bioavailability and half-life are intertwined concepts; you can't think about one without the other.

Minor cannabinoids like CBG and THCV have far less published PK data. That's worth saying plainly: the half-life literature for the minor cannabinoids is thin and most of what exists comes from small-sample or preclinical studies. I'd be cautious about anyone who quotes precise half-life figures for CBG in humans with great confidence. Precision without a solid evidence base is a warning sign in itself.

Peptides: short half-lives, by design and by problem

If cannabinoids have unusually long half-lives for small molecules, peptides tend to sit at the opposite end of the spectrum. Native peptide hormones are often cleared within minutes in plasma. Enzymes called peptidases cleave the peptide bonds between amino acids aggressively, and the kidneys filter short peptides efficiently. Evolution built fast clearance in deliberately, you want hormonal signals to switch off cleanly. Our pieces on peptide half-life and peptide pharmacokinetics cover the mechanics, and peptides versus small-molecule drugs explains why the two categories behave so differently.

The pharmaceutical challenge is extending half-life enough that a peptide remains pharmacologically relevant for a useful window. The engineering solutions are clever: PEGylation (attaching polyethylene glycol chains to slow renal filtration), albumin binding, fatty acid conjugation, and cyclic peptide structures that resist enzymatic cleavage. For the first of these, see PEGylation and half-life extension. GLP-1 receptor agonists are a well-documented example of this, native GLP-1 has a half-life of roughly two minutes in plasma, whilst some synthetic analogues achieve half-lives of over a week, enabling once-weekly subcutaneous injection schedules.

It's worth being direct here: many peptides currently marketed in Australia for performance or body composition purposes are unapproved therapeutic goods. The TGA has made clear that supplying unapproved peptides; including many sold under research or grey-market labels, is illegal under the Therapeutic Goods Act 1989. Unapproved doesn't mean unstudied; it means the safety, quality, and efficacy dossier hasn't been assessed and the product isn't on the Australian Register of Therapeutic Goods (ARTG). Half-life data on these compounds in human subjects is often absent or derived from animal studies with uncertain translation. For background on how labels like these are used, see "research use only" loopholes explained.

Elimination half-life versus effective duration

One distinction I find myself explaining often: half-life and duration of effect are not the same thing.

A receptor agonist might have a plasma half-life of two hours but bind so tightly to its target that the pharmacological effect lasts twelve. Conversely, a prodrug with a long plasma half-life might be inactive until metabolised, with the active metabolite cleared quickly. The PK profile (what the body does to the drug) and the PD profile (what the drug does to the body) are related but separate curves. Half-life describes the former. Duration of effect depends on both.

This is part of why translating in vitro binding data directly into dosing predictions is unreliable. The concentration at the receptor site isn't simply plasma concentration, tissue distribution, protein binding, active transport at cell membranes, and local metabolism all shape what actually reaches the target. The article on plasma proteins and drug binding shows how much a bound fraction can change the picture, since only the unbound portion is generally free to act or be cleared.

Individual variation: the number is never one number

Published half-life values are population means, usually from healthy adults in controlled conditions. Real-world variation is substantial.

Hepatic function matters enormously. The cytochrome P450 enzyme family; particularly CYP2C9, CYP2C19, and CYP3A4, handles the oxidative metabolism of a vast proportion of drugs. Genetic polymorphisms in these enzymes mean that what is a four-hour half-life in a "typical" metaboliser might be two hours in a rapid metaboliser or eight hours in a poor metaboliser. Age-related decline in hepatic and renal function extends half-lives in older adults. Body composition shifts Vd. Drug interactions at metabolic enzymes can extend or shorten half-life dramatically. Two related reads here are how the liver metabolises drugs and cannabinoids and CYP450 drug interactions.

Honestly, the single published t½ figure should be read as an anchor point, not a prescription. It tells you the order of magnitude and the general shape of the curve. The specific value in any individual will deviate, sometimes substantially.

When you see a half-life quoted, a few questions are worth asking. Who was studied, and were they healthy adults or a narrower group? Was the figure from a single dose or repeated dosing? Was it a plasma value or a terminal value from the slow tail? Did the study involve humans at all? A number stripped of that context can look authoritative whilst telling you very little. Keep the number, but keep its limits in view too.

Half-life is a simple idea that rewards patience. Once the arithmetic is comfortable, the rest of pharmacokinetics tends to fall into place around it.

Sources

• Pharmacokinetics; StatPearls, National Library of Medicine (NCBI)
• Cannabinoid Pharmacokinetics and Pharmacodynamics, Cannabis and Cannabinoid Research, NCBI PMC
• Therapeutic Goods Act 1989 Overview, Therapeutic Goods Administration (TGA)
• Half-Life and Dosing Interval in Clinical Pharmacology; British Journal of Clinical Pharmacology, NCBI PMC

Priya Nandakumar, Pharmacology writer, peptides & PK